Results 241 to 250 of about 64,427 (282)

Thermodynamic Study of Solubility for Imatinib Mesylate in Nine Monosolvents and Two Binary Solvent Mixtures from 278.15 to 318.15 K

Journal of Chemical and Engineering Data, 2018
The solubility of imatinib mesylate in nine monosolvents and two binary solvents was determined by the shaken flask method followed by UV composition analysis from 278.15 to 318.15 K at atmospheric pressure.
Xinyi Wang, Dejiang Zhang, Shiyuan Liu, Yifu Chen, L. Jia, Songgu Wu   +5 more
semanticscholar   +1 more source

Another Look at Imatinib Mesylate

New England Journal of Medicine, 2006
Imatinib mesylate may affect particular signaling pathways that increase susceptibility to congestive heart failure.
Axel Ullrich, Klaus Strebhardt
openaire   +3 more sources

Role of Imatinib Mesylate in Osteoblastogenesis.

Blood, 2007
Abstract Imatinib mesylate (IM), a tyrosine kinase inhibitor, currently used in chronic myeloid leukaemia (CML) may also affect the growth of other cellular systems besides CML cells. It has been reported that IM may affect bone tissue remodeling mainly by an inhibitory activity on osteoclastogenesis.
D. TIBULLO, C. GIALLONGO, P. LA CAVA, S. BERRETTA, F. STAGNO, A. CHIARENZA, G. A. PALUMBO, DI RAIMONDO, FRANCESCO   +7 more
openaire   +3 more sources

Imatinib Mesylate (Gleevec) Hepatotoxicity

Digestive Diseases and Sciences, 2007
Imatinib mesylate (Gleevec; Novartis Pharmaceuticals Corporation, East Hanover, NJ), formerly known as STI571, is a specific inhibitor of BCR-ABL tyrosine kinase. It is widely used for the treatment of patients with Philadelphia chromosome-positive chronic myeloid leukemia (CML) and c-kit (CD117) positive unresectable and/or metastatic malignant ...
Eugene R. Schiff, Ayse L. Mindikoglu, Arie Regev, Enrique J. Martinez, Pablo A. Bejarano, Lennox J. Jeffers   +5 more
openaire   +3 more sources

Imatinib mesylate in thymic epithelial malignancies

Cancer Chemotherapy and Pharmacology, 2011
Thymic epithelial tumors (TETs) are rare tumors of the mediastinum, with an estimated incidence of about 3 cases per 100,000 inhabitants. Although anthracycline- and platinum-based chemotherapy is an active treatment for TETs, novel systemic therapeutic options are especially needed for metastatic disease, which is virtually incurable.
PALMIERI, GIOVANNELLA, Marino M., BUONERBA, CARLO, FEDERICO, piera, Conti S., Milella M., Petillo L., Evoli A., Lalle M., Ceribelli A., Merola G., MATANO, ELIDE, Sioletic S., DE PLACIDO, SABINO, DI LORENZO, GIUSEPPE, DAMIANO, VINCENZO   +15 more
openaire   +4 more sources

Imatinib mesylate in the treatment of hematologic malignancies

Expert Opinion on Biological Therapy, 2007
The treatment of hematologic malignancies has been based for many years on chemotherapy and possibly, for the more aggressive forms, stem cell transplantation. In 2001, the signal transduction inhibitor 571 (STI571, imatinib mesylate) was reported to have striking effects in chronic myeloid leukaemia patients.
PICCALUGA, PIER PAOLO, RONDONI, MICHELA, PAOLINI, STEFANIA, ROSTI, GIANANTONIO, MARTINELLI, GIOVANNI, BACCARANI, MICHELE   +5 more
openaire   +4 more sources

Imatinib mesylate-induced acute hepatotoxicity

Journal of Oncology Pharmacy Practice, 2023
Introduction Imatinib is a first-line selective tyrosine kinase inhibitor used for the treatment of chronic myeloid leukemia. Although imatinib-induced hepatotoxicity may aggravate the patient's clinical condition and alter the treatment plan, the mechanism of imatinib-induced hepatotoxicity has rarely been investigated. Case report We report a 51-year-
Imen Frikha, Yousra Fakhfakh, Rim Sahnoun, Lassaad Chtourou, Moez Medhaffar, Moez Elloumi   +5 more
openaire   +2 more sources

Polycythemia Vera Responds to Imatinib Mesylate

The American Journal of the Medical Sciences, 2003
We report 2 patients with polycythemia vera who were demonstrated to be -negative and were unable to tolerate either hydroxyurea or interferon-alpha but who had excellent clinical responses to imatinib mesylate (STI-571). This effect is consistent with the inhibitory effect of imatinib mesylate on c-kit's tyrosine kinase activity as demonstrated by its
Tina M. Dickinson, C. Michael Jones
openaire   +3 more sources

A validated LC method for imatinib mesylate

Journal of Pharmaceutical and Biomedical Analysis, 2003
An isocratic reversed-phase liquid chromatography method with UV detection has been developed for the purity evaluation of imatinib mesylate in bulk drug. The method is selective and is capable of detecting all process intermediates and other related compounds, which may be present at trace levels in the drug substance.
D Sreenivas Rao, N. M. Sekhar, Ganesan Vaidyanathan, V.V Vivekanand, P Ramachandra Puranik, S Avijit Kelkar   +5 more
openaire   +3 more sources

Treatment of polycythemia vera with imatinib mesylate

Leukemia Research, 2012
We treated 37 patients with polycythemia vera with imatinib mesylate (IM). The overall response rate was 49%. Thirty percent had a complete response, and 19%, a partial response. Thirty-one patients were treated for >120 days. Frequent side effects included nausea, diarrhea, edema, and skin rash.
Eric J. Feldman, Katherine Vandris, A. Salvado, Richard T. Silver, Jerry L. Spivak, Michael H. Bourla, Steven M. Fruchtman   +6 more
openaire   +3 more sources